Vertex Pharmaceuticals (VRTX) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Vertex Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$11.02B

Latest Revenue (Q)

$2.96B

Main Segment (Y)

TRIKAFTA/KAFTRIO

Main Geography (Y)

UNITED STATES

Vertex Pharmaceuticals Revenue by Period

Vertex Pharmaceuticals Revenue by Year

Date	Revenue	Change
2024-12-31	$11.02B	11.66%
2023-12-31	$9.87B	10.51%
2022-12-31	$8.93B	17.91%
2021-12-31	$7.57B	22.06%
2020-12-31	$6.21B	49.07%
2019-12-31	$4.16B	36.59%
2018-12-31	$3.05B	22.46%
2017-12-31	$2.49B	46.20%
2016-12-31	$1.70B	64.89%
2015-12-31	$1.03B	77.86%
2014-12-31	$580.41M	-52.11%
2013-12-31	$1.21B	-20.63%
2012-12-31	$1.53B	8.25%
2011-12-31	$1.41B	883.91%
2010-12-31	$143.37M	40.49%
2009-12-31	$102.05M	-41.85%
2008-12-31	$175.50M	-11.81%
2007-12-31	$199.01M	-8.02%
2006-12-31	$216.36M	34.47%
2005-12-31	$160.89M	56.63%
2004-12-31	$102.72M	48.56%
2003-12-31	$69.14M	-57.08%
2002-12-31	$161.09M	-3.82%
2001-12-31	$167.49M	114.38%
2000-12-31	$78.13M	26.83%
1999-12-31	$61.60M	38.74%
1998-12-31	$44.40M	1.37%
1997-12-31	$43.80M	229.32%
1996-12-31	$13.30M	-39.82%
1995-12-31	$22.10M	12.76%
1994-12-31	$19.60M	-29.75%
1993-12-31	$27.90M	-

Vertex Pharmaceuticals generated $11.02B in revenue during NA 2024, up 11.66% compared to the previous quarter, and up 264.73% compared to the same period a year ago.

Vertex Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2025-06-30	$2.96B	7.02%
2025-03-31	$2.77B	-4.87%
2024-12-31	$2.91B	5.05%
2024-09-30	$2.77B	4.77%
2024-06-30	$2.65B	-1.55%
2024-03-31	$2.69B	6.73%
2023-12-31	$2.52B	1.38%
2023-09-30	$2.48B	-0.39%
2023-06-30	$2.49B	4.99%
2023-03-31	$2.37B	3.13%
2022-12-31	$2.30B	-1.35%
2022-09-30	$2.33B	6.29%
2022-06-30	$2.20B	4.71%
2022-03-31	$2.10B	1.20%
2021-12-31	$2.07B	4.46%
2021-09-30	$1.98B	10.64%
2021-06-30	$1.79B	4.01%
2021-03-31	$1.72B	5.93%
2020-12-31	$1.63B	5.82%
2020-09-30	$1.54B	0.90%
2020-06-30	$1.52B	0.62%
2020-03-31	$1.52B	7.21%
2019-12-31	$1.41B	48.79%
2019-09-30	$949.83M	0.91%
2019-06-30	$941.29M	9.65%
2019-03-31	$858.43M	-1.34%
2018-12-31	$870.11M	10.91%
2018-09-30	$784.53M	4.30%
2018-06-30	$752.16M	17.38%
2018-03-31	$640.80M	-1.66%
2017-12-31	$651.63M	12.71%
2017-09-30	$578.16M	6.25%
2017-06-30	$544.13M	-23.87%
2017-03-31	$714.72M	55.81%
2016-12-31	$458.71M	10.86%
2016-09-30	$413.78M	-4.13%
2016-06-30	$431.61M	8.42%
2016-03-31	$398.08M	-4.75%
2015-12-31	$417.94M	34.90%
2015-09-30	$309.82M	86.55%
2015-06-30	$166.08M	19.90%
2015-03-31	$138.51M	-4.18%
2014-12-31	$144.56M	-19.24%
2014-09-30	$178.99M	29.31%
2014-06-30	$138.42M	16.86%
2014-03-31	$118.45M	-66.27%
2013-12-31	$351.16M	58.39%
2013-09-30	$221.70M	-28.66%
2013-06-30	$310.75M	-5.37%
2013-03-31	$328.37M	-1.68%
2012-12-31	$333.99M	-0.60%
2012-09-30	$336.01M	-19.67%
2012-06-30	$418.31M	-4.66%
2012-03-31	$438.74M	-22.12%
2011-12-31	$563.34M	-14.54%
2011-09-30	$659.20M	476.10%
2011-06-30	$114.42M	55.34%
2011-03-31	$73.66M	12.42%
2010-12-31	$65.52M	175.37%
2010-09-30	$23.80M	-24.75%
2010-06-30	$31.62M	40.99%
2010-03-31	$22.43M	-33.82%
2009-12-31	$33.89M	35.79%
2009-09-30	$24.96M	30.91%
2009-06-30	$19.06M	-20.50%
2009-03-31	$23.98M	-26.92%
2008-12-31	$32.81M	3.80%
2008-09-30	$31.61M	-54.46%
2008-06-30	$69.41M	66.55%
2008-03-31	$41.67M	-

Vertex Pharmaceuticals generated $2.96B in revenue during Q2 2025, up 7.02% compared to the previous quarter, and up 110.33% compared to the same period a year ago.

Vertex Pharmaceuticals Revenue Breakdown

Vertex Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
TRIKAFTA/KAFTRIO	$10.24B	$8.94B	$7.69B	$5.70B	$3.86B
Product	-	$9.87B	-	-	-
KALYDECO	-	$475.50M	$553.20M	$684.20M	$802.87M
ORKAMBI	-	$326.00M	$510.70M	$771.60M	$907.51M
SYMDEKO/SYMKEVI	-	$123.00M	$180.00M	$420.40M	$628.58M
Collaborative and Royalty	-	-	-	$1.00M	$2.90M

Vertex Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 24: TRIKAFTA/KAFTRIO (100.00%).

Quarterly Revenue by Product

Product/Service	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
ALYFTREK	$156.80M	$53.90M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Manufactured Product, Other	$236.10M	$170.80M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
TRIKAFTA/KAFTRIO	$2.55B	$2.54B	$2.72B	$2.58B	$2.45B	$2.48B	$2.33B	$2.27B	$2.24B	$2.10B	$2.02B	$2.01B	$1.89B	$1.76B	$1.69B	$1.56B	$1.26B	$1.19B	$1.09B	$960.31M
Collaborative and Royalty	-	$10.00M	-	$900.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
SYMDEKO/SYMKEVI	-	-	-	-	-	-	$27.80M	$33.40M	$31.20M	$30.60M	$34.30M	$38.20M	$42.70M	$64.80M	$80.43M	$81.42M	$133.50M	$125.05M	$127.51M	$156.18M
KALYDECO	-	-	-	-	-	-	$112.40M	$112.80M	$125.30M	$125.00M	$136.10M	$139.40M	$138.70M	$139.00M	$152.15M	$162.42M	$183.29M	$186.34M	$193.37M	$193.87M
ORKAMBI	-	-	-	-	-	-	$44.20M	$63.00M	$96.30M	$122.50M	$110.80M	$146.20M	$121.60M	$132.10M	$147.38M	$184.56M	$220.97M	$218.70M	$215.47M	$225.92M

Vertex Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: TRIKAFTA/KAFTRIO (86.65%), Manufactured Product, Other (8.02%), and ALYFTREK (5.33%).

Vertex Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Non-US	$5.22B	$4.55B	-	-	-
Europe	$3.45B	$3.11B	$2.71B	$1.97B	$1.13B
UNITED STATES	$6.68B	$6.04B	$5.70B	$5.29B	$4.83B
Outside the United States	-	$3.83B	$3.23B	$2.29B	$1.38B
Other Countries Outside of the United States and Europe	-	$719.80M	$525.90M	$313.20M	$249.94M

Vertex Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (43.53%), Non-US (33.97%), and Europe (22.49%).

Quarterly Revenue by Country

Country	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Sep 22	Jun 22	Mar 22	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20
Europe	$910.90M	$826.60M	$832.00M	$847.70M	$806.80M	$967.40M	$735.30M	$766.50M	$800.00M	$807.20M	$730.50M	$655.50M	$632.30M	$518.83M	$458.91M	$404.97M	$360.02M	$251.37M	$257.68M	$257.39M
Other, Non U.S.	$205.60M	$280.10M	$210.70M	$224.50M	$203.30M	$162.80M	$185.40M	$163.80M	$148.20M	$125.60M	$97.00M	$82.45M	$77.54M	$64.90M	$62.34M	$56.49M	$70.13M	-	-	-
Non-US	$1.32B	$1.39B	$1.96B	$1.06B	$1.03B	$1.17B	$929.30M	$985.40M	$971.00M	$878.70M	$781.10M	$729.30M	$601.27M	$536.45M	$469.87M	$313.71M	$314.17M	$327.52M	-	-
UNITED STATES	$1.83B	$1.65B	$1.84B	$1.71B	$1.61B	$1.52B	$1.57B	$1.55B	$1.51B	$1.40B	$1.46B	$1.42B	$1.37B	$1.38B	$1.26B	$1.25B	$1.21B	$1.22B	$1.21B	$1.19B

Vertex Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Jun 25: UNITED STATES (42.84%), Non-US (30.99%), Europe (21.35%), and Other, Non U.S. (4.82%).

Vertex Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
CVS	CVS Health	$372.81B	$98.92B
MCK	McKesson	$308.95B	$97.83B
HCA	HCA Healthcare	$70.60B	$18.61B
BMY	Bristol-Myers Squibb	$48.30B	$12.27B
SNY	Sanofi	$43.07B	$11.12B
MDT	Medtronic	$33.54B	$8.58B
GSK	GSK	$30.33B	$7.36B
REGN	Regeneron Pharmaceuticals	$14.20B	$3.75B
VRTX	Vertex Pharmaceuticals	$11.02B	$2.96B
ARGX	argenx SE	$1.23B	$401.00M

VRTX Revenue FAQ

What is Vertex Pharmaceuticals’s yearly revenue?

Vertex Pharmaceuticals's yearly revenue for 2024 was $11.02B, representing an increase of 11.66% compared to 2023. The company's yearly revenue for 2023 was $9.87B, representing an increase of 10.51% compared to 2022. VRTX's yearly revenue for 2022 was $8.93B, representing an increase of 17.91% compared to 2021.

What is Vertex Pharmaceuticals’s quarterly revenue?

Vertex Pharmaceuticals's quarterly revenue for Q2 2025 was $2.96B, a 7.02% increase from the previous quarter (Q1 2025), and a 12.06% increase year-over-year (Q2 2024). The company's quarterly revenue for Q1 2025 was $2.77B, a -4.87% decrease from the previous quarter (Q4 2024), and a 3.09% increase year-over-year (Q1 2024). VRTX's quarterly revenue for Q4 2024 was $2.91B, a 5.05% increase from the previous quarter (Q3 2024), and a 15.66% increase year-over-year (Q4 2023).

What is Vertex Pharmaceuticals’s revenue growth rate?

Vertex Pharmaceuticals's revenue growth rate for the last 3 years (2022-2024) was 23.40%, and for the last 5 years (2020-2024) was 77.58%.

What are Vertex Pharmaceuticals’s revenue streams?

Vertex Pharmaceuticals's revenue streams in c 24 are TRIKAFTA/KAFTRIO

What is Vertex Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Vertex Pharmaceuticals was TRIKAFTA/KAFTRIO. This segment made a revenue of $10.24B, representing 100.00% of the company's total revenue.